|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 5:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Blum HE: Treatment of hepatocellular
carcinoma. Best Pract Res Clin Gastroenterol. 19:129–145. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shimokawa H, Uramoto H, Onitsuka T, et al:
Overexpression of mACC1 mRNA in lung adenocarcinoma is associated
with postoperative recurrence. J Thorac Cardiovasc Surg. 4:895–898.
2011. View Article : Google Scholar
|
|
4
|
Shirahata A, Sakata M, Kitamura Y, et al:
MACC1 as a marker for peritoneal-disseminated gastric carcinoma.
Anticancer Res. 30:3441–3444. 2010.PubMed/NCBI
|
|
5
|
Shirahata A, Shinmura K, Kitamura Y, et
al: MACC1 as a marker for advanced colorectal carcinoma. Anticancer
Res. 30:2689–2692. 2010.PubMed/NCBI
|
|
6
|
Arlta F and Stein U: Colon cancer
metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem
Cell Biol. 41:2356–2359. 2009. View Article : Google Scholar
|
|
7
|
Huang Y, Zhang H, Cai J, et al:
Overexpression of MACC1 and Its significance in human breast cancer
progression. Cell Biosci. 1:162013. View Article : Google Scholar
|
|
8
|
Gao J, Ding FH, Liu QG and Yao YM:
Knockdown of MACC1 expression suppressed hepatocellular carcinoma
cell migration and invasion and inhibited expression of MMP2 and
MMP9. Mol Cell Biochem. 376:21–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stein U, Walther W, Arlt F, et al: MACC1,
a newly identified key regulator of HGF-MET signaling, predicts
colon cancer metastasis. Nat Med. 15:59–67. 2009. View Article : Google Scholar
|
|
10
|
Qiu J, Huang P, Liu Q, et al:
Identification of MACC1 as a novel prognostic marker in
hepatocellular carcinoma. J Transl Med. 9:166–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wallace DC: Mitochondria and cancer:
Warburg addressed. Cold Spring Harb Symp on Quantit Biol.
70:363–374. 2005. View Article : Google Scholar
|
|
12
|
Mathupala SP, Rempel A and Pedersen PL:
Aberrant glycolytic metabolism of cancer cells: a remarkable
coordination of genetic, transcriptional, post-translational, and
mutational events that lead to a critical role for type II
hexokinase. J Bioenerg Biomembr. 29:339–343. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bustamante E and Pedersen PL: High aerobic
glycolysis of rat hepatoma cells in culture: role of mitochondrial
hexokinase. Proc Natl Acad Sci USA. 74:3735–3739. 1977. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bustamante E, Morris HP and Pedersen PL:
Energy metabolism of tumor cells: requirement for a form of
hexokinase with a propensity for mitochondrial binding. J Biol
Chem. 256:8699–8704. 1981.PubMed/NCBI
|
|
15
|
Pastorino JG and Hoek JB: Hexokinase II:
the integration of energy metabolism and control of apoptosis. Curr
Med Chem. 10:1535–1551. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sattler M and Salgia R: c-Met and
hepatocyte growth factor: potential as novel targets in cancer
therapy. Curr Oncol Rep. 9:102–108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lang AH, Geller-Rhomberg S, Winder T, et
al: A common variant of the MACC1 gene is significantly associated
with overall survival in colorectal cancer patients. BMC Cancer.
12:202012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ahn KJ, Hwang HS, Park JH, et al:
Evaluation of the role of hexokinase type II in cellular
proliferation and apoptosis using human hepatocellular carcinoma
cell lines. J Nucl Med. 50:1525–1532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roberts DJ, Tan-Sah VP, Smith JM and
Miyamoto S: Akt phosphorylates HK-II at Thr473 and increases
mitochondrial HK-II association to protect cardiomyocytes. J Biol
Chem. 288:23798–23806. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Albers I, Hartmann H, Bircher J and
Creutzfeldt W: Superiority of the Child-Pugh classification to
quantitative liver function tests for assessing prognosis of liver
cirrhosis. Scand J Gastroenterol. 24:269–276. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shephard DA: The 1975 Declaration of
Helsinki and consent. Can Med Assoc J. 115:1191–1192.
1976.PubMed/NCBI
|
|
22
|
Liu F, Yang T, Wang B, et al: Resistin
induces insulin resistance, but does not affect glucose output in
rat-derived hepatocytes. Acta Pharmacol Sin. 29:98–104. 2008.
View Article : Google Scholar
|
|
23
|
Xie C, Wu J, Yun J, et al: MACC1 as a
prognostic biomarker for early-stage and AFP-normal hepatocellular
carcinoma. PLoS One. 8:e642352013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ge SH, Wu XJ, Wang XH, et al:
Over-expression of metastasis-associated in colon cancer-1 (MACC1)
associated with better prognosis of gastric cancer patients. Chin J
Cancer Res. 23:153–159. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gottlob K, Majewski N, Kennedy S, Kandel
E, Robey RB and Hay N: Inhibition of early apoptotic events by
Akt/PKB is dependent on the first committed step of glycolysis and
mitochondrial hexokinase. Genes Dev. 15:1406–1418. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bijur GN and Jope RS: Rapid accumulation
of Akt in mitochondria following phosphatidylinositol 3-kinase
activation. J Neurochem. 87:1427–1435. 2003. View Article : Google Scholar
|
|
27
|
Neary CL and Pastorino JG: Akt inhibition
promotes hexokinase 2 redistribution and glucose uptake in cancer
cells. J Cell Physiol. 228:1943–1948. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu Y, Pereira RO, O’Neill BT, et al:
Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake
independent of mTORC1 and GLUT4 translocation. Mol Endocrinol.
27:172–184. 2013. View Article : Google Scholar :
|
|
29
|
Gwak GY, Yoon JH, Kim Km, Lee HS, Chung JW
and Gores GJ: Gores. Hypoxia stimulates proliferation of human
hepatoma cells through the induction of hexokinase II expression. J
Hepatol. 42:358–364. 2005. View Article : Google Scholar : PubMed/NCBI
|
